The Ministry of Public Health (MOPH), led by the Minister of Public Health, H.E. Mr Pattana Promphat, together with six partners from the research and pharmaceutical sectors, have signed a Memorandum of Understanding (MOU) to promote clinical research on medicines and vaccines.
The initiative aims to strengthen the country’s clinical research system to meet international standards, provide Thai patients with faster access to innovative treatments, facilitate regulatory registration, attract investment, and establish Thailand as a regional centre for clinical research.
The six participating organisations included the Food and Drug Administration (FDA); the Thailand Clinical Research Foundation; the Health Systems Research Institute; the National Vaccine Institute (NVI); the Pharmaceutical Research and Manufacturers Association; and the Thai Pharmaceutical Manufacturers Association.
Mr Pattana emphasised, “Clinical research is a key driver for developing modern medicines and vaccines and forms the foundation of national health security. Strengthening this capability will enable Thai citizens to access innovative treatments more rapidly, reduce reliance on imported medicines, and support the long-term growth of Thailand’s pharmaceutical and medical technology sectors.”
He said the collaboration is expected to integrate efforts across all sectors includes international partners, develop an efficient clinical research network and minimise approval redundancies, as well as elevate research conducts to international standards.
Ms Supattra Boonserm, Secretary-General of the FDA, noted, “Access to treatment is a fundamental right for all Thais.” She added that clinical research increases opportunities for patients, particularly those with rare diseases, to access innovative therapies sooner.
Developing the national clinical research system requires cooperation across government, research units, hospitals, and industry.
The MOU serves as a crucial mechanism to systematically connect stakeholders, covering researcher development, research facilities, and ethical standards. Supporting domestic clinical research, along with regulatory facilitation for medicines and vaccines, will strengthen Thailand’s research units internationally, attract foreign R&D investment, and position Thailand as a regional hub for clinical research in the future.
The MOU signing event also featured an academic panel discussion on “Perspectives on Multi-Regional Clinical Trials (MRCT) and the Future of Thailand’s Health System”, with participation from executives of the signatory organisations.
Other highlight also included the exhibition booth showcasing the institute’s National Vaccine Security Policy and Strategic Plan (2023–2027) as well as Thailand’s vaccine development and manufacturing capabilities. The Institute was represented by Director, Dr Nakorn Premsri, and Deputy Director, Dr Sunate Chuenkitmongkol, together with executives and staff.
